MedTrace Logo

Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids

NCT01563913 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2018-06-29

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to measure the safety (side effects) of an Omega 3 Fatty acid called docosahexanoic acid (DHA) and measure the dyskinesia (involuntary movements) in Parkinson 's disease (PD).

Conditions

Interventions

DRUG

Docosahexaenoic Acid (DHA)

Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years

DRUG

Placebo

Sugar Pill, taken for 1.5 years

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Kathryn Anne Chung, MD · VA Portland Health Care System, Portland, OR

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01563913 on ClinicalTrials.gov